ArticleNature2019
Small molecule combats cancer-causing KRAS protein at last.
Article in Nature, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Design of new drugs for medullary thyroid carcinoma.Frontiers in oncology · 2022Pooled it
- Prognostic role of tumor microenvironment and immune- and autophagy-related genes in colorectal adenocarcinoma.Translational cancer research · 2025Article
- CHARMM-GUI PDB Reader and Manipulator: Covalent Ligand Modeling and Simulation.Journal of molecular biology · 2024Article
- Recent advances in targeting the "undruggable" proteins: from drug discovery to clinical trials.Signal transduction and targeted therapy · 2023Review
- Antitumor pharmacological research in the era of personalized medicine.Acta pharmacologica Sinica · 2022Review
- Label-free cell tracking enables collective motion phenotyping in epithelial monolayers.iScience · 2022Article
- FDA-Approved Small Molecule Compounds as Drugs for Solid Cancers from Early 2011 to the End of 2021.Molecules (Basel, Switzerland) · 2022Review
- A Breakthrough Brought about by Targeting KRASCancers · 2022Review
- Non-genetic adaptive resistance to KRASFrontiers in oncology · 2022Review
- Distinct roles of tumor associated mutations in collective cell migration.Scientific reports · 2021Article
- KRAS gene polymorphisms are associated with the risk of glioma: a two-center case-control study.Translational pediatrics · 2021Article
- Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome.Translational lung cancer research · 2021Article
- The Research Progress of Direct KRAS G12C Mutation Inhibitors.Pathology oncology research : POR · 2021Review
- Future perspectives from lung cancer pre-clinical models: new treatments are coming?Translational lung cancer research · 2020Review
- Non-Coding RNAs in Lung Tumor Initiation and Progression.International journal of molecular sciences · 2020Review
- Rapid Improvement of the Performance Status and Reduction of the Tumor Size in KRAS-Mutated Colorectal Cancer Patient Receiving Binimetinib, Hydroxychloroquine, and Bevacizumab.Case reports in oncologyArticle
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
31705127What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.